Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $65.85 --0%
EPS Growth %: +22.5%
Financial Fact:
Selling, general and administrative (2): 111.49M
Today's EPS Names:
FCNCA, PBCO, ARBV, More
EPS Growth %: +22.5%
Financial Fact:
Selling, general and administrative (2): 111.49M
Today's EPS Names:
FCNCA, PBCO, ARBV, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q4 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $180.7 million versus the consensus estimate of $179.2 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Albertsons (ACI) Misses Q1 EPS by 12c; offers guidance
- Bankwell Financial Group, Inc. (BWFG) Tops Q2 EPS by 23c
- Freeport-McMoran (FCX) Tops Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
